Search Follow us

Kiadis Pharma (KDS)

Business description

Kiadis Pharma is a Dutch biotech company developing a modified donor T-cell infusion (ATIR) given after a stem-cell transplant to treat acute leukaemia.

A smart approach to stem cell transplantation

QuickView | Pharmaceutical & healthcare | 09/11/2016

Kiadis Pharma is developing T cell-based therapies to address the issues associated with haematopoietic stem cell transplantation (HSCT). The company is leveraging its Theralux technology to develop ATIR101 and ATIR201 as adjunct therapies to HSCT in leukaemia and thalassemia, respectively. On the back of Phase II data, Kiadis is aiming for accelerated filing of ATIR101 with the European Medicines Agency (EMA) in Q117. A Phase III trial will start in H216. ATIR201 will start a Phase I/II trial in H216. Cash at end June 2016 was €23.7m, sufficient to fund operations until early 2018. We value the company at €327.3m or €27.1/share.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€201.2m
Last close€10.000
High / Low (52 weeks)€13.4 / €5.2
Stock market listingEU
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(0.7)(3)66.9

* % Relative to local index

Company news